Analysis of the Efficacy of Bevacizumab Combined with TP Regimen Chemotherapy in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer
Objective To investigate the effect of chemotherapy with bevacizumab combined with TP regimen in the treatment of advanced non-small cell lung cancer(NSCLC).Methods 60 patients with advanced NSCLC admitted to our hospital from January 2022 to September 2023 were selected as the study objects,and were divided into a control group and an observation group according to random number table method,with 30 cases in each group.The control group received TP regimen chemotherapy,and the observation group received bevacizumab combined with TP regimen chemotherapy.The clinical efficacy,clinical symptom score,serum markers and quality of life of the two groups were compared.Results The clinical effect of observation group was 86.67%higher than 60.00%of the control group,the difference was statistically significant(P＜0.05).After treatment,the clinical symptom score,serum carcinoembryonic antigen,neuronal specific enolase and vascular endothelial growth factor levels in observation group were lower than those in control group,and the score of Quality of Life core Questionnaire was higher than that in control group,with statistical significance between the two groups(P＜0.05).Conclusion Chemotherapy with bevacizumab combined with TP regimen is effective in the treatment of advanced NSCLC patients,which can effectively improve clinical symptoms,reduce serum markers and improve their quality of life.
NETL
NSTL
万方数据
